IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3KÎ´ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Indolent Non-hodgkin Lymphoma
DRUG: IBI376
Objective Response Rate (ORR), To assess the efficacy of IBI376 in terms of objective response rate (ORR) in subjects with relapsed or refractory follicular lymphoma (FL)/Marginal lymphoma(MZL). Subjects will be evaluated for ORR by an IRC (Lugano criteria), 2 years
Complete Response Rate (CRR), To assess complete response rate (CRR), 2 years|Duration of Response (DOR), To assess the duration of response (DOR), 2 years|Progression-free Survival (PFS), To assess progression-free survival (PFS), 2 years|Overall Survival (OS), To assess overall survival (OS), 2 years|Best percentage change in target lesion size, To assess best percentage change in target lesion size, 2 years|Safety and tolerability of IBI376 measured by adverse events (AEs), Defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment., Baseline through 30-35 days after end of treatment, up to approximately 12 months per subject
Patients will be recruited for 2 cohorts. Cohort A will recruit 58 RRFL subjects, and Cohort B will recruit 62 RRMZL subjects.